8-K: Tonix Pharmaceuticals Partners with KEMRI for Mpox Vaccine Clinical Trial

Tonix Pharmaceuticals has announced a research partnership with the Kenya Medical Research Institute (KEMRI) to conduct a Phase I clinical trial for its TNX-801 mpox vaccine candidate.

Summary

• Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute (KEMRI) to design and conduct a Phase I clinical trial in Kenya for their TNX-801 vaccine candidate.
• The trial will assess the safety, tolerability, and immunogenicity of TNX-801 as a vaccine to prevent mpox and smallpox.
• Tonix will sponsor the trial, while KEMRI will lead its execution.
• TNX-801 is a live, attenuated horsepox vaccine designed to provide immune protection against mpox.
• Preclinical data suggests TNX-801 is effective against mpox in animal models and aligns with the World Health Organization's (WHO) preferred target product profile for mpox vaccines.
• The WHO has declared mpox a public health emergency of international concern, highlighting the need for effective vaccines.
• The vaccine is designed to be a single-dose vaccine with durable protection, and can be manufactured, distributed and stored without a costly supply chain.

Sentiment

Score: 8

Explanation: The document is positive due to the partnership, the potential of the vaccine, and the alignment with WHO recommendations. However, it is still early in the development process, so there are risks.

Positives

• The partnership with KEMRI provides access to a research institute to conduct the clinical trial.
• TNX-801 has shown promising preclinical results, including protection against lethal mpox challenge in animals.
• The vaccine is designed for single-dose administration, which is advantageous over two-dose regimens.
• TNX-801 has demonstrated decreased virulence in immunocompromised animals compared to older vaccinia viruses.
• The vaccine's design aligns with the WHO's preferred target product profile for mpox vaccines.
• The vaccine can be scaled up for manufacturing, distribution and storage without a costly supply chain.

Negatives

• The document does not mention any negative aspects of the partnership or the vaccine itself.
• The document does not mention any negative aspects of the clinical trial.

Risks

• The clinical trial is still in Phase I, and there is no guarantee of success.
• The vaccine's efficacy and safety in humans have not yet been established.
• There are risks associated with obtaining regulatory approvals.
• The company faces competition in the development of mpox vaccines.
• The company may require additional financing to support the development of TNX-801.

Future Outlook

The company plans to advance the development of TNX-801 through the Phase I clinical trial in Kenya, with the goal of making a single-dose mpox vaccine with durable protection available worldwide.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that they are excited to advance development of TNX-801 under this research agreement with KEMRI.
• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that there is an urgent need for the worldwide availability of a single dose mpox vaccine with durable protection.
• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that they believe TNX-801 has the potential to address and help interrupt the spread of mpox worldwide.

Industry Context

This announcement is relevant given the ongoing mpox outbreaks and the need for effective vaccines. The partnership with KEMRI and the focus on a single-dose vaccine align with global health priorities.

Comparison to Industry Standards

• The development of a single-dose mpox vaccine aligns with recommendations from the Bipartisan Commission on Biodefense and the U.S. National Academies of Science.
• The use of a live, attenuated horsepox vaccine is a novel approach compared to traditional vaccinia-based vaccines.
• The collaboration with Bilthoven Biologics for GMP manufacturing is a standard practice in vaccine development.
• The focus on a vaccine that can be stored at ambient temperature addresses a key logistical challenge in vaccine distribution.

Stakeholder Impact

• Shareholders may view this partnership positively, as it advances the development of a potential product.
• Employees may be motivated by the progress in the company's pipeline.
• The partnership could lead to a potential vaccine for mpox, benefiting public health.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The next step is to design, plan, and seek regulatory approval for the Phase I clinical trial in Kenya.
• The company will then conduct the Phase I clinical trial to assess the safety, tolerability, and immunogenicity of TNX-801.

Key Dates

Keywords

Mpox, Vaccine, TNX-801, Clinical Trial, KEMRI, Infectious Disease, Public Health, Horsepox, WHO, Immunogenicity